Original articleLymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients
Introduction
Lymphomatoid papulosis (LyP) is a rare CD30+ lymphoproliferative disorder. The estimated worldwide incidence is 1.2 to 1.9 cases per 1.000.000 people1 with a 10-year survival rate close to 100%.2 Although the peak incidence is in the fifth decade, any age group can be affected. Men are more likely to have LyP than women.3, 4
The first to report this disease was Dupont in 19655; 3 years later, Macaulay introduced the term lymphomatoid papulosis and described it as benign, self-regressing erythematous papules with malignant histology.6 By definition, LyP lesions are red or purple (sometimes pruritic) papules and nodules, measuring less than 2.0 cm. They occur as single or multiple crops and can affect any body part. In half of the patients, the lesions heal with scar formation.3 The tendency to regress spontaneously is characteristic for the disease and crucial to establish a clinical diagnosis.7 Larger nonregressing lesions, in contrast, would be expected in primary cutaneous anaplastic large cell lymphoma (ALCL) or mycosis fungoides (MF) tumor lesions with CD30+ expression.4
Over the years, the subclassification of LyP has become very precise and is a work in progress.8 The most common LyP subtype is type A, characterized by a wedge-shaped infiltrate with neutrophils, eosinophils, and histiocytes. Type B has small- to medium-sized lymphocytes with cerebriform nuclei, simulating features observed in MF. Type C has sheets of large CD30+ lymphocytes, resembling ALCL.9 Other rare types include type D, with predominantly CD8+ lymphocytic infiltrates10 and type E, characterized by angiodestructive infiltrates of small- to medium-sized lymphocytes expressing CD30 and CD8.11 A sixth, type F, is currently proposed and described as having a perifollicular infiltrate with folliculotropism.12
Previous smaller studies, including our first report of LyP patients 10 years ago, suggested a possible association of LyP and development of secondary lymphomas.3, 4, 13, 14, 15, 16 To date, no curative treatment for LyP is available.17 Information regarding the potential of aggressive therapy on prevention of secondary lymphomas is lacking.
The purpose of this study was to define LyP characteristics, risk factors, associated malignancies, long-term outcome, and response to currently available treatment options in a large cohort from the MD Anderson Cancer Center, Clinic for Cutaneous T-cell Lymphomas.
Section snippets
Patients
This was a retrospective study of patients with LyP seen at the MD Anderson Cancer Center, Houston between 1999 and 2015 aimed to bring continuity to our previously published cohort of 84 patients in the follow-up period from 1999 to 2005.16 The study protocol was approved by the institutional review board (#PA15-0324). A total of 237 patients with LyP were identified, searching the MD Anderson Cancer Center cutaneous T-cell lymphoma database. The diagnosis of LyP was made according to the
Statistical analysis
Basic summary statistics were used to describe demographic data, treatment types, and response. Continuous data are expressed as mean ± standard deviation (SD) or median (range), as appropriate. Categorical data were assessed using Pearson's χ2 test. Kaplan Meier time-to-event curves were used to study disease progression from time of LyP diagnosis to secondary lymphoma development. All analyses were performed using SPSS version 22.0 (SPSS Inc, Chicago, IL). P < .05 was considered statistically
Patient characteristics
A total of 180 patients were evaluated (Table I). Mean follow-up time was 60.5 ± 56.5 months. A male predominance was observed, with 56.7% being male. Most were white (77.2%). Mean age at diagnosis was 52.7 ± 17.2 years. There was no difference in age of disease onset for sex or ethnicity (P = .157; P = .816). The mean time from symptom onset to biopsy-proven LyP was 45.0 ± 75.4 months. Pruritus was reported to be the primary symptom in 55.3% of all patients. Half of the patients (51.6%) had
Discussion
Here we report our experience with LyP and provide the largest cohort of patients published to date. We address the key features of LyP, associated lymphomas, and currently available treatment options. In previous studies with smaller sample sizes, the prevalence of associated lymphomas with LyP varied considerably between 9.5% and 61%.3, 13, 14, 15 We observed that 93 patients (52%) had one or more secondary malignancies before, concomitant to, or after LyP diagnosis (Fig 3). A total of 26% of
References (26)
- et al.
WHO-EORTC classification for cutaneous lymphomas
Blood
(2005) - et al.
In search of prognostic indicators for lymphomatoid papulosis: A retrospective study of 123 patients
J Am Acad Dermatol
(2012) - et al.
Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment
J Am Acad Dermatol
(1993) - et al.
Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings
J Am Acad Dermatol
(2013) - et al.
CD30+ cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma
J Am Acad Dermatol
(2003) - et al.
Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment
Blood
(2000) - et al.
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
Blood
(2011) - et al.
Lymphomatoid papulosis: a clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor gene rearrangement studies
J Am Acad Dermatol
(1994) - et al.
Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin
Hum Pathol
(2015) - et al.
Lymphomatoid papulosis associated with mycosis fungoides: A study of 21 patients including analyses for clonality
J Am Acad Dermatol
(2003)
Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders
J Am Acad Dermatol
Epidemiology of lymphomatoid papulosis
Cancer
Survival data for 299 patients with primary cutaneous lymphomas: A monocentre study
Acta Derm Venereol
Cited by (95)
Clinicopathological Factors Associated with the Prognosis and Chronicity of Lymphomatoid Papulosis: A Retrospective Cohort Study
2022, Clinical Lymphoma, Myeloma and LeukemiaAn unusual case of cluster of differentiation 30–positive T-cell lymphoproliferative disorder manifesting as mandibular gingival ulceration: A case report
2022, Journal of the American Dental AssociationSelf-regressing oral CD30-positive, EBV-negative, T-cell lymphoproliferative lesions. A poorly understood process highlighted by ominous clinicopathologic features and indolent behavior
2021, Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyPrimary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management
2021, Journal of the American Academy of DermatologyCitation Excerpt :Less common AEs include fatigue, nausea/gastrointestinal distress, alopecia, and reversible, mild neutropenia.16 Other reported therapies with variable efficacy include topical agents (nitrogen mustard and imiquimod) and systemic agents (interferon and oral retinoids).6,9 PC-ALCL commonly presents as a single, rapidly growing, often ulcerated nodule/tumor, although approximately 20% of patients present with multiple/disseminated lesions.1,17
Recurrent and Persistent Lymphomatoid Papulosis in an Elderly Male with Hodgkin's Lymphoma
2021, American Journal of Medicine
Funding sources: None.
Conflicts of interest: Dr Duvic: Seattle genetics (research funding for clinical trials and advisory board); all other authors have no conflict of interest to declare.